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Abstract 
Voltage-gated sodium (NaV) channels play a central role in the propagation of action 
potentials in excitable cells in both humans and insects. Many venomous animals have 
therefore evolved toxins that modulate the activity of NaV channels in order to subdue their 
prey and deter predators. Spider venoms in particular are rich in NaV channel modulators, 
with one third of all known ion channel toxins from spider venoms acting on NaV channels. 
Here we review the landscape of spider-venom peptides that have so far been described to 
target vertebrate or invertebrate NaV channels. These peptides fall into 12 distinct families 
based on their primary structure and cysteine scaffold. Some of these peptides have become 
useful pharmacological tools, while others have potential as therapeutic leads because they 
target specific NaV channel subtypes that are considered to be important analgesic targets. 
Spider venoms are conservatively predicted to contain more than 10 million bioactive 
peptides and so far only 0.01% of this diversity been characterised. Thus, it is likely that 
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Introduction 
More than 42,700 extant species of spiders have been described (Platnick, 1997), with an 
even greater number remaining to be characterised (Coddington and Levi, 1991), making 
them the largest group of terrestrial predators. One of the major contributors to the 
evolutionary success of spiders is their ability to produce complex venoms for predation and 
predator deterrence (King, 2004). Spider venoms are complex chemical cocktails but the 
major components are small, disulfide-rich peptides. Since a single venom can contain as 
many as 1,000 peptides, it has been conservatively estimated that >10 million bioactive 
peptides are likely to be present in the venoms of spiders (Escoubas et al., 2006), with only 
0.01% of this diversity having been characterised. The spider-venom peptides that have been 
described to date are detailed in ArachnoServer, a manually curated database that provides 
detailed information about proteinaceous toxins from spiders (Wood et al., 2009; Herzig et al., 
2011).  
 
Voltage-gated sodium (NaV) channels play a key role in the rising phase of the action 
potential in excitable cells (Catterall et al., 2005). In contrast with vertebrates, insects express 
only a single NaV channel subtype (King et al., 2008a) and consequently they are extremely 
sensitive to NaV channel modulators, as underlined by the fact that several of the most 
successful classes of chemical insecticides are NaV channel modulators (e.g., pyrethroids, 
indoxacarb, dihydropyrazoles, N-alkylamides, and DDT) (Soderlund and Knipple, 1995; 
Bloomquist et al., 1996; Zlotkin, 1999). One-third of the 186 ion channel modulators listed in 
ArachnoServer target NaV channels (Fig. 1), which is perhaps not surprising as these toxins 
allow spiders to rapidly incapacitate their prey. NaV channel toxins are found in a 
taxonomically diverse range of spiders, which suggests that this pharmacology was recruited 
at a very early stage in venom gland evolution. Moreover, the ubiquity of NaV channel toxins 
in spider venoms suggests that these peptides might be useful insecticides for the control of 
arthropod pests (Maggio et al., 2010; Windley et al., 2012). 
 
In addition to prey capture, spiders also use their venom to deter predators, which can include 
vertebrates. Moreover, even though the vast majority of spiders prey primarily on 
invertebrates, there is no evolutionary selection pressure to prevent spider toxins acting on 
vertebrate ion channels. It is therefore not surprising that many spider-venom peptides have 
been found to modulate the activity of vertebrate NaV channels (Nicholson and Little, 2005; 
Escoubas and Bosmans, 2007; King et al., 2008a). 
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NaV channels 
In both vertebrates and invertebrates, functional NaV channels are composed primarily of a 
large pore-forming α subunit (220–260 kDa) whose gating and kinetics are modified via 
association with one of four smaller β subunits (33–36 kDa) in the case of vertebrates or the 
unrelated TipE accessory subunit (65 kDa) in the case of invertebrates (King et al., 2008a). 
The α subunit is composed of four homologous but non-identical domains (designated I–IV) 
connected by intracellular linkers (Fig. 2). Each of these domains contains six transmembrane 
(TM) segments (S1–S6) joined by intracellular or extracellular loops. Membrane re-entrant 
loops between TM segments S5 and S6 dip into the TM region of the protein and form the 
narrow ion-selectivity filter at the extracellular end of the pore (Fig. 2). During action 
potential generation, the channel cycles through three states: closed, open, and inactivated. 
The S4 segments contain a positively charged amino acid (Arg or Lys) at every third position; 
this segment serves as a ‘voltage sensor’ that initiates voltage-dependent activation (i.e., the 
transition from the closed to open state) by responding to membrane depolarization and 
causing the channel to undergo a conformational change that allows selective influx of Na+ 
ions through the pore. Sodium channel inactivation (i.e., the transition from the open to 
inactivated state) is mediated by a short intracellular loop termed the “inactivation gate” that 
connects domains III and IV (Fig. 2). In a major breakthrough, the three-dimensional 
structure of a bacterial NaV channel in the closed state was recently determined (Payandeh et 
al., 2011), which should allow molecular modelling of the interaction between NaV channels 
and ligands that modulate their activity. 
 
In vertebrates, the α subunits are classified into nine different subtypes, denoted NaV1.1 to 
NaV1.9, and they are further characterised by their sensitivity to tetrodotoxin (TTX). NaV1.5, 
NaV1.8 and NaV1.9 are TTX-resistant, whereas all other subtypes are TTX-sensitive (Catterall 
et al., 2005; King et al., 2008a). A combination of site-directed mutagenesis, binding studies, 
and electrophysiological approaches have been used to identify at least seven distinct ligand 
binding sites in or around the pore region of the NaV channel α subunit, as shown in Fig. 2. 
The majority of these sites have been identified using venom molecules and alkaloids as 
pharmacological probes (King et al., 2008a). Venom peptides modulate channel activity by 
two main mechanisms: they either physically occlude the channel pore or they bind to an 
allosteric site that induces a conformational change in the channel that alters the equilibrium 
between the open, closed, and inactivated states (Ekberg et al., 2008). 
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All known NaV channel toxins from spider venoms are allosteric modulators, also known as 
“gating modifiers”. However, they modulate channel activity in quite different ways. For 
example, the lethal toxin from the Sydney funnel-web spider Atrax robustus (δ-HXTX-Ar1a) 
inhibits the inactivation of both insect and vertebrate NaV channels (Nicholson et al., 1998; 
Grolleau et al., 2001), whereas the µ-agatoxins from unrelated American funnel spiders shift 
the voltage for channel activation to more negative potentials, increasing the probability of 
channel opening at the resting membrane potential (Adams, 2004). 
 
Spider toxins that target NaV channels 
The primary aim of this review is to survey the range of peptide sequences and three-
dimensional scaffolds that have been evolved by spiders for targeting NaV channels, with an 
emphasis on those peptides that might have therapeutic potential. The ‘Browse by Molecular 
Targets’ ontology in ArachnoServer (Wood et al., 2009; Herzig et al., 2011) was used to 
extract all known spider-venom peptides with activity on NaV channels (both vertebrate and 
invertebrate). Homologs of these toxins were found by using the BLAST function within 
ArachnoServer. CLC sequence viewer 6 (CLC bio, Denmark) was used to align the peptides 
and generate families of related peptides based on the level of sequence identity and 
intercysteine spacings. This resulted in 12 different families of spider-venom peptides that 
target NaV channels, as outlined in Figures 3 and 4. The following sections describe the 
activity data that is currently available for each family. These sections employ the rational 
nomenclature recently developed for spider-venom peptides (King et al., 2008b) in order to 
facilitate identification of orthologs and paralogs, but for convenience we also provide 
original names of toxins. The term NaScTx is employed for scorpion toxins that target NaV 
channels (Rodriguez de la Vega and Possani, 2005), and here we introduce the term NaSpTx 
for spider toxins that target this channel. 
 
Family 1: All peptides in Family 1 were isolated from the venom of tarantulas 
(Theraphosidae), and they consist of 33–35 amino acid residues with three disulfide bridges 
that form an inhibitor cystine knot (ICK) motif, defined as an antiparallel β sheet stabilised by 
a cystine knot (Pallaghy et al., 1994). In spider toxins, the β sheet typically comprises only 
two β strands although a third N-terminal strand is sometimes present (King et al., 2002). The 
cystine knot itself comprises a ring formed by two disulfides and the intervening sections of 
the peptide backbone, with a third disulfide piercing the ring to create a pseudo-knot (Saez et 
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al., 2010). This “knot” converts ICK peptides into hyperstable mini-proteins with tremendous 
chemical, thermal, and biological stability. ICK toxins are typically resistant to extremes of 
pH, organic solvents, high temperatures, and proteases (Saez et al., 2010). Of the 10 families 
of NaSpTxs whose disulfide connectivity has been determined or which can be confidently 
predicted based on homology (see Figures 3 and 4), nine contain an ICK motif. 	  
One member of Family 1 (µ/ω-TRTX-Hh1a; huwentoxin-1) was found to be analgesic in a rat 
model of formalin-induced pain when administered intrathecally (Chen et al., 2005), although 
in another study the same peptide was reported to be lethal to mice when delivered via the 
intraperitoneal or intracisternal route (Liang et al., 1993). Intraperitoneal administration of 
µ-TRTX-Hhn1b (hainantoxin-IV) is also lethal to mice with an LD50 of 0.2 mg/kg (Liu et al., 
2003), as is intracerebroventricular (i.c.v.) administration of β-TRTX-Ps1a (phrixotoxin-3), 
β-TRTX-Cm1a (ceratotoxin-1), and β-TRTX-Cm1b (ceratotoxin-1) (Bosmans et al., 2006). 
 
Despite the high level of residue conservation throughout this family, the selectivity of the 
peptides for the various NaV channel subtypes varies dramatically. For example, β-TRTX-
Ps1a potently blocks NaV1.5 with an IC50 of 72 nM (Bosmans et al., 2006) whereas µ-TRTX-
Hh2a (huwentoxin-4), which is 62% identical to β-TRTX-Ps1a, does not have any effect on 
NaV1.5 at concentrations up to 10 µM (Xiao et al., 2008). Based on homology with other 
toxins, peptides in Family 1 are presumed to function as gating modifiers (Bosmans et al., 
2006). Consistent with this hypothesis, analysis of the binding of µ-TRTX-Hh2a to mutants 
of NaV1.4 revealed that the peptide interacts with the S3-S4 linker of channel domain II (i.e., 
neurotoxin receptor site 4; see Fig. 2), with the blocking effect achieved by trapping the 
domain II voltage sensor in the closed configuration (Xiao et al., 2008). In contrast, µ-TRTX-
Hhn1b was shown to have no effect on the activation or inactivation kinetics of TTX-S NaV 
currents in rat dorsal root ganglion (DRG) neurons and therefore it was hypothesised to 
function not as a gating modifier but as a pore blocker by binding at neurotoxin receptor site 1 
(Li et al., 2004). However, this would be a very unusual pharmacology for NaSpTxs and it 
remains to be confirmed by site-directed mutagenesis and competitive binding studies. The 
functionally important residues on µ-TRTX-Hhn1b have been proposed to be K27 (which is 
conserved in most Family 1 peptides) and R29 (which is poorly conserved) as mutations of 
these residues to alanine showed reduced activity (Li et al., 2004). 
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Very little work has been done to examine the activity of Family 1 peptides against insect NaV 
channels, but the limited data available indicates that the insecticidal activity of these peptides 
is likely to be highly variable. µ-TRTX-Hhn1b has no effect when injected into cockroaches 
(Liu et al., 2003), whereas µ/ω-TRTX-Hh1a potently inhibits NaV currents in cockroach 
dorsal unpaired median (DUM) neurons (IC50 = 4.8 nM) (Wang et al., 2011). Falling between 
these two extremes is µ-TRTX-Hhn2b (hainantoxin-I), which only weakly inhibits insect NaV 
channels heterologously expressed in Xenopus oocytes (IC50 = 4.3 µM) (Li et al., 2003).  
 
Family 2: Family 2 is the largest family of NaSpTxs with 34 members, all originating from 
theraphosid venoms. Of these, 18 peptides were isolated from the Chinese tarantula 
Chilobrachys jingzhao. Family 2 peptides range in size from 33–41 residues and they each 
contain three disulfide bonds that form an ICK motif. Currently, there is experimental proof 
of NaV channel activity for only four of the 34 peptides in this family. However, they are very 
interesting from a therapeutic perspective as one member of this family, β/ω-TRTX-Tp1a 
(protoxin I), is one of the most potent blockers of human NaV1.7 reported to date, with an IC50 
of 51 nM (Middleton et al., 2002; Priest et al., 2007). 
 
κ-TRTX-Cj1a (Jingzhaotoxin-11) is a weak modulator of NaV currents in cardiac myocytes 
(i.e., mainly TTX-R NaV1.5), causing a significant reduction in peak NaV current amplitude 
and a slowing of NaV current inactivation (IC50 = 1280 nM) (Liao et al., 2006). It also inhibits 
KV2.1 with moderate potency (IC50 = 740 nM), with even weaker block of KV4.1 and KV4.2 
and no effect on KV1.1, KV1.2, KV1.3, KV1.4 and KV3.1 (Liao et al., 2006). A peptide with 
identical sequence has been isolated from the venom of the related theraphosid spider 
Plesiophrictus guangxiensis. It has been proposed that κ-TRTX-Cj1a binds to the 
extracellular S3–S4 linker region of channel domain IV (i.e., neurotoxin receptor site 3; see 
Fig. 2) (Liao et al., 2006), which is a common target of gating modifier toxins such as 
κ-TRTX-Gr1a (Hanatoxin-1) in the same family (Li-Smerin and Swartz, 1998). 
 
β-TRTX-Cm2a (Ceratotoxin-3) has moderate affinity towards NaV1.5 (IC50 = 447 nM), and at 
a concentration of 2 µM it weakly blocks NaV1.8 (45% reduction in current) but has no 
activity against NaV1.1–1.4 (Bosmans et al., 2006). In striking contrast with κ-TRTX-Cj1a 
and β-TRTX-Cm2a, µ-TRTX-Cj1a (Jingzhaotoxin-34) is a potent blocker of TTX-S NaV 
channels in rat dorsal root ganglion (DRG) neurons (IC50 = 85 nM) but it has no effect on 
8 
TTX-R NaV currents (Chen et al., 2009). Thus, residues that are conserved in κ-TRTX-Cj1a 
and β-TRTX-Cm2a, but which are absent from µ-TRTX-Cj1a, should provide some insight 
into residues that are important for interaction of this family of peptides with NaV1.5. 
 
Six toxins from Family 2 have confirmed activity on voltage-gated calcium (CaV) channels, 
with 12 toxins active against KV channels. Nevertheless, the high level of sequence identity 
within this family and the potency of the known Family 2 NaV modulators described above 
indicates that a thorough functional analysis of all toxins in this family could reveal many 
more toxins acting on NaV channels. However, from a therapeutic perspective, the 
promiscuous activity of several family members on multiple types of voltage-gated channels 
indicates that it will be critical to carefully determine the selectivity of any Family 2 peptides 
that are being considered as therapeutic leads (Chen et al., 2008). 
 
Family 3: This family consists of 14 reported toxins with highly conserved sequences in the 
C-terminal region. κ-TRTX-Ps1b (Phrixotoxin-2) and κ-TRTX-Gr2a (GsMTx-2) are identical 
peptides identified from different genera of tarantulas (Diochot et al., 1999; Oswald et al., 
2002); for simplicity, only κ-TRTX-Ps1b is given in the alignment (Fig. 3). Family 3 peptides 
are 29–32 residues long, with three disulfide bonds forming an ICK motif. These peptides act 
as gating modifiers by binding to the voltage-sensor region (S3–S4 linker) of channel domain 
II (i.e., neurotoxin receptor site 4; see Fig. 2), thus impeding channel activation and causing 
the channels to remain in an inactivated state (Sokolov et al., 2007). β/ω-TRTX-Tp2a 
(protoxin II) and β-TRTX-Gr1b (GsAF I) are both selective against the NaV1.7 subtype, an 
important analgesic target, but their potency differs by >100-fold despite ~90% sequence 
identity (Priest et al., 2007; Redaelli et al., 2010). β/ω-TRTX-Tp2a is the most potent blocker 
of human NaV1.7 reported to date, with an IC50 of 0.3 nM (Schmalhofer et al., 2008). It also 
inhibits activation of human CaV3.1 currents but at much higher doses (IC50 ~1 µM) 
(Edgerton et al., 2010). β/ω-TRTX-Tp2a is lethal to rats when administered intravenously at 
doses ≥1.0 mg/kg or intrathecally at doses ≥0.1 mg/kg (Schmalhofer et al., 2008). This is 
perhaps not surprising as even though β/ω-TRTX-Tp2a preferentially blocks NaV1.7, it also 
potently inhibits key peripheral NaV channel subtypes (e.g., NaV1.5, IC50 = 79 nM) as well as 
central NaV channel subtypes (e.g., NaV1.2, IC50 = 41 nM) (Schmalhofer et al., 2008). 
 
β-TRTX-Gr1a (GrTx1) is 96% identical to β-TRTX-Gr1b, with the only difference being a 
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Gln at position 22 instead of Arg. However, this single amino acid change causes a vast 
difference in selectivity. β-TRTX-Gr1a has similar potency towards NaV1.1, NaV1.2, NaV1.3, 
NaV1.6, and NaV1.7 (IC50 range of 230–770 nM) whereas β-TRTX-Gr1b is >5-fold more 
selective towards NaV1.7 (Redaelli et al., 2010). Significant variations in NaV channel subtype 
selectivity due to small sequence variations has been noted previously in scorpion-venom 
peptides (Weinberger et al., 2010). 
 
Family 4: Of the seven peptides in this family, six were isolated from the venom of 
Australian funnel-web spiders (family Hexathelidae), whereas the seventh is found in non-
related Australian mouse spiders (family Actinopodidae). These peptides comprise 42–44 
residues with four disulfide bonds, three of them arranged in an ICK motif. They are 
characterised by an unusual sequence of three consecutive Cys residues in the centre of the 
primary structure and a disulfide bond that connects the N- and C-terminal Cys residues. All 
peptides in this family are lethal to vertebrates, including δ-HXTX-Ar1a (robustoxin) from 
the Sydney funnel-web spider Atrax robustus, which was responsible for at least 14 human 
fatalities prior to the introduction of an effective antivenom in 1980 (Fletcher et al., 1997). 
Family 4 peptides bind to neurotoxin receptor site 3 (see Fig. 2) and slow inactivation of both 
vertebrate TTX-sensitive NaV channels and insect para-type NaV channels (Gunning et al., 
2003; Nicholson et al., 2004). Symptoms in primates include immediate disturbances in 
respiration, blood pressure and heart rate, followed by severe hypotension and death due to 
respiratory and circulatory failure within a few hours (Mylecharane et al., 1989). With the 
exception of δ-HXTX-Hv1b (Szeto et al., 2000), all Family 4 peptides exhibit insecticidal 
activity, causing paralysis and/or lethality in orthopterans, lepidopterans and dipterans (Little 
et al., 1998; Grolleau et al., 2001). 
 
The activity of δ-HXTX-Mg1a (Magi-4), the only member of this family not isolated from an 
Australian funnel-web spider, was recently tested against the full range of rodent NaV 
subtypes expressed in oocytes (Yamaji et al., 2009). δ-HXTX-Mg1a was found to be a potent 
blocker of the Drosophila para/TipE NaV channel (IC50 ~ 23 nM), and it potently slowed NaV 
channel inactivation in cockroach DUM neurons (EC50 ~820 pM) (Yamaji et al., 2009). 
Activity on vertebrate NaV subtypes was much more modest, perhaps explaining why 
envenomation by Macrothele gigas does not appear to be a serious medical problem. At a 
concentration of 5 µM, δ-HXTX-Mg1a had a significant effect on inactivation of rat NaV1.1 
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and mouse NaV1.6, modest effects on rat NaV1.2, NaV1.3 and NaV1.7, and no effect on rat 
NaV1.4, rat NaV1.5 and human NaV1.8. In contrast with δ-HXTX-Mg1a, Family 4 toxins from 
lethal Australian funnel-web spiders, such as δ-HXTX-Hv1a, are more potent on vertebrate 
TTX-sensitive NaV channels than insect NaV channels (Nicholson et al., 1996). 
 
Family 5: This family of NaSpTxs comprises only two peptides isolated from closely related 
hexathelid spiders, both of the genus Macrothele. These peptides contain 28–29 residues with 
three disulfide bonds forming an ICK motif. β-HXTX-Mg1a (Magi-5) and β-HXTX-Mr1a 
(raventoxin III), from different species of Macrothele, have identical sequences (Zeng et al., 
2003) so only β-HXTX-Mg1a is presented in the alignment. These peptides are lethal to 
rodents, but their insecticidal activity is variable. Intra-thoracic injection of U12-HXTX-Mg1a 
(Magi-11) in crickets (Gryllus bimaculatus) induced slow-onset paralysis leading to death, 
while intracranial injection in mice resulted in lacrimation, sweating, and urination followed 
by paralysis of breathing and death 15 min post-injection. β-HXTX-Mg1a/β-HXTX-Mr1a 
caused reversible paralysis when injected into caterpillars (Spodoptera litura) and had no 
effect when injected into cockroaches (Periplaneta americana), whereas intraperitoneal 
injection in mice resulted in excitation, gasping, spastic paralysis, and exophthalmos (bulging 
of the eyes) followed by death (Satake et al., 2004). β-HXTX-Mg1a binds to site 4 on 
vertebrate NaV channels (see Fig. 2) and shifts steady-state activation to more hyperpolarised 
voltages, whereas it has been reported to bind to site 3 on insect channels (Corzo et al., 2003; 
Zeng et al., 2003; Corzo et al., 2007) 
 
Family 6: All peptides in this family were isolated from the venom of spiders in the family 
Ctenidae. Four were isolated from the highly venomous Brazilian armed spider Phoneutria 
nigriventer, one was isolated from the venom of the closely related P. reidyi, and one was 
identified from a venom gland transcriptome of P. keyserlingi. The final member of the 
family was isolated from the venom of a related ctenid, the South American fishing spider 
(Ancylometes sp.). These toxins comprise 47–54 residues and contain five disulfide bonds 
whose connectivity has not been experimentally determined. Of those that have been tested in 
vertebrates, all display lethality even at doses as low as 7.5 pmol/g (Cordeiro et al., 1992). 
δ-CNTX-Pn2a (Tx2-6) has a complex pharmacology that results in inhibition of NaV channel 
inactivation and a hyperpolarizing shift in the potential required for channel activation 
(Matavel et al., 2002). Due to the high sequence identity (80–89%) between members of this 
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family, they are all assumed to modulate NaV channels in this manner. An interesting 
supplementary pharmacology has been observed for δ-CNTX-Pn2a, which originated from 
the observation that males bitten by this spider experience a diverse variety of symptoms 
including priapism. Although i.c.v. injection of δ-CNTX-Pn2a into rats is lethal, rats with 
depressed erectile function can be normalised by subcutaneous administration of δ-CNTX-
Pn2a (Nunes et al., 2008). A minimum dose of only 0.006 µg/kg was required to cause an 
erection in mice when injected directly into the corpus cavernosum and, at this dose, no local 
and systemic toxic effects were observed (Andrade et al., 2008). Thus, δ-CNTX-Pn2a has 
been touted as a lead molecule for the development of new therapeutics for treatment of 
erectile dysfunction that might have fewer side effects than current drugs. 
 
Only limited information is available regarding the insecticidal activity of members of this 
family. δ-CNTX-Pn2a and -Pn2b (Tx2-5) were reported to be insecticidal to both the larval 
and adult forms of the house fly Musca domestica (Cordeiro et al., 1992), however, no LD50 
values have been reported.  
 
Family 7: All peptides in this family were isolated from the venom of theraphosid spiders. 
They each contain 33–36 residues with three disulfide bonds that form an ICK motif. 
κ-TRTX-Pg1b (guangxitoxin-1) and κ-TRTX-Cj3a (jingzhaotoxin-4), isolated from different 
genera, are identical (Herrington et al., 2006; Chen et al., 2008), so only the sequence of 
κ-TRTX-Pg1b is presented in the alignment. These peptides appear to have promiscuous 
activity on both KV and NaV channels. Although several family members were isolated as KV 
channel blockers, these peptides have not been tested on NaV channels. The only two family 
members that have been directly tested on NaV channels displayed significant activity. Both 
β/κ-TRTX-Cj1a (jingzhaotoxin-3) and δ-TRTX-Cj1a (jingzhaotoxin-1) inhibit activation of 
NaV1.5 with an IC50 of 350 nM and 32 nM, respectively (Xiao et al., 2005; Rong et al., 2011), 
It was recently shown via mutational studies that β/κ-TRTX-Cj1a binds to the S3–S4 loop of 
domain II (i.e., neurotoxin receptor site 4; see Fig. 2) in NaV1.5 (Rong et al., 2011).  
 
Little is known about the insecticidal activity of these toxins. Intra-abdominal injection of 
µ-TRTX-Hh1a (Huwentoxin-3) into cockroaches induces reversible paralysis that lasts for 
several hours. The effects of other family members on insects or heterologously expressed 
insect NaV channels have not been examined. 
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Family 8: This is a small family comprising only three peptides derived from two species of 
ctenid spiders. These peptides are easily the longest NaSpTxs, with 76–77 residues and seven 
disulfide bonds. They are similar in size to scorpion α and β toxins that also target NaV 
channels (Rodriguez de la Vega and Possani, 2005), but they have no sequence homology and 
contain a larger number of disulfide bonds. These toxins are lethal to rodents. µ-CNTX-Pn1a 
(Tx1; PhTx1) from P. nigriventer has an LD50 of 5.5 pmol/g in mice (Diniz et al., 1990; Diniz 
et al., 2006), while U5-CNTX-Pk1b (PKTx1B) caused excitation and spastic paralysis in mice 
upon i.c.v. administration at a dose of 1.5 µg/mouse, followed by death within 5–8 min 
(Richardson et al., 2006). 
 
Preliminary studies suggested that µ-CNTX-Pn1a might target vertebrate CaV channels 
(Gouvea dos Santos et al., 1999; Gouvea dos Santos et al., 2002) but more recent studies have 
shown that it is a state-dependent blocker of rat NaV1.2 that binds in the vicinity of channel 
site 1 (Martin-Moutot et al., 2006). The high level of sequence identity suggests that all 
members of this family will have the same pharmacology. 
 
Family 9: This family consists of only two paralogous peptides isolated from the venom of 
the crab spider Heriaeus melloteei. They comprise 37 and 40 residues, with three disulfide 
bonds that are predicted to form an ICK motif.  µ-TMTX-Hme1a (Hm-1) has similar potency 
against NaV1.2, NaV1.4, NaV1.5, and NaV1.6. (IC50 150–500 nM) but no effect against NaV1.8 
(Billen et al., 2008). µ-TMTX-Hme1b (Hm-2) has similar pharmacology, except that it has 
very little activity against NaV1.5 (Billen et al., 2008). The insecticidal activity of these toxins 
has not been examined. 
 
Family 10: This family comprises venom peptides from the closely related spider families 
Amaurobiidae and Agelenidae. All members of Family 10 are 36–38 residues long and 
contain four disulfide bonds, three of which form an ICK motif. With the exception of 
δ-AMATX-Pl1a (δ-palutoxin IT1), all members of Family 10 are C-terminally amidated. The 
µ-agatoxins (µ-AGTXs) in Family 10 shift the voltage-activation curve to more negative 
potentials, increasing the probability of NaV channel opening at the resting membrane 
potential. The resultant membrane depolarization leads to calcium entry into nerve terminals 
and spontaneous release of neurotransmitter into the neuromuscular junction, as well as 
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repetitive action potentials in motor neurons (Skinner et al., 1989; Adams, 2004). The 
δ-amaurobitoxins, previously known as δ-palutoxins (Corzo et al., 2000), have a quite 
different mode of action to the µ-agatoxins. They bind to site 4 on insect NaV channels (Ferrat 
et al., 2005) and inhibit channel inactivation, but they have no effect on rat NaV1.2 channels at 
concentrations up to 10 µM (Ferrat et al., 2005). They are the only spider toxins that have 
been definitively shown to bind to site 4 on insect NaV channels but which modulate NaV 
channel inactivation (King et al., 2008a)(Windley et al., 2012). 
 
The only toxic effect in vertebrates reported for any member of Family 10 was a temporary 
paralysis (lasting not longer than 15 min) of the left legs of a mouse that received an i.c.v. 
injection of 486 pmol of δ-AMATX-Pl1b (δ-palutoxin IT2) (Corzo et al., 2000). However, a 
wide range of insecticidal activities have been reported for Family 10 peptides. The 
δ-amaurobitoxins are weakly insecticidal, with LD50 values of 2347–11029 pmol/g when 
injected into larvae of the moth Spodoptera litura (Corzo et al., 2000). The µ-AGTXs from 
Agelenopsis aperta induced irreversible spastic paralysis when injected into range of insects, 
with µ-AGTX-Aa1d (µ-agatoxin IV) being particularly potent in the housefly Musca 
domestica with an LD50 of 30 pmol/g (Skinner et al., 1989). The µ-AGTXs from Hololena 
curta caused rapid irreversible flaccid paralysis when injected into house crickets (Acheta 
domestica) (Stapleton et al., 1990). 
 
Family 11: Family 11 comprises a group of three paralogous insecticidal peptides isolated 
from the primitive weaving spider Diguetia canities. These toxins are 56–59 residues long 
with four disulfide bonds whose configuration has not been experimentally determined. The 
most potent of the three peptides, µ-diguetoxin-Dc1a (DTX9.2), causes rapid paralysis of 
lepidopteran larvae with a PD50 of 380 pmol/g, but it is not toxic to mice at doses up to 
657 pmol/g (Krapcho et al., 1995). Neurophysiological experiments indicate that these toxins 
are highly specific insect NaV channel activators that induce hyperexcitability in sensory 
insect nerves and repetitive ﬁring in skeletal muscles (Bloomquist et al., 1996). The fact that 
the peptides are not toxic to mice suggests that they are unlikely to have potent effects on 
vertebrate NaV channels. 
 
Family 12: This family consists of three paralogous insecticidal peptides isolated from the 
hexathelid spider Macrothele gigas. They comprise 38–40 residues with three disulfide bonds 
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that are predicted to form an ICK motif. These peptides bind specifically to site 3 on insect 
NaV channels, but they have no effect on NaV channels from rat brain synaptosomes and are 
not toxic to mice when injected i.c.v. at a dose of 20 pmol/g (Corzo et al., 2003). 
 
Discussion 
Recruitment of NaV toxins into spider venoms 
Spiders appear to have evolved a significantly larger repertoire of NaV channel toxins than 
any other venomous animal. Since insects only express a single NaV channel subtype that 
plays a crucial role in action potential generation (King et al., 2008a), this channel is an 
excellent target for insect predators wishing to rapidly incapacitate their prey. Thus, it is not 
surprising that spiders seem to have recruited NaV channel toxins into their venoms at a very 
early stage of venom evolution. 
 
With only a few exceptions, the members within each of the 12 different classes of NaV 
channel toxins outlined in this review were restricted to certain taxonomic families. For 
example, all peptides in Families 1 and 2 were isolated from spiders of the family 
Theraphosidae, whereas all peptides in Family 6 originated from spiders in the Ctenidae 
family. The only exceptions are Family 10, with toxins from the closely related spider 
families Amaurobiidae and Agelenidae, and Family 4, with toxins from the spider families 
Hexathelidae and Actinopodidae, which are not closely related but which belong both to the 
suborder Mygalomorphae. This correlation between NaV channel toxin classes and spider 
families can be easily visualised (see Figures 3–4) using the rational nomenclature developed 
for spider-venom peptides (King et al., 2008b), which makes it easy to identify orthologous 
and paralogous relationships. While the close relationship between toxin classes and spider 
families superficially suggests that spiders recruited particular NaV toxin scaffolds at specific 
stages during the course of spider evolution, it seems more likely that most of these scaffolds 
are ancient recruitments and that deep phylogenetic relationships are currently obscured by 
the relatively poor taxonomic sampling of spider venoms. There are currently ~42,700 
characterised species of spiders, yet venom peptides have been isolated from less than 100. 
 
Comparison with NaV channel toxins from other venomous animals 
Only two related families of scorpion-venom peptides have been described that target NaV 
channels; they have been separated based on their pharmacological properties and are denoted 
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the α and β families (Gordon et al., 2007). These so-called long-chain toxins comprise 58–76 
residues and they are typically stabilised by four disulfide bonds with a 1–8, 2–5, 3–6, 4–7 
connectivity (Rodriguez de la Vega and Possani, 2005). These toxins have a  βαββ topology 
that is unrelated to any known spider-toxin scaffolds. Like Family 4 NaSpTxs, scorpion α 
toxins interact with NaV channel site 3 and delay channel inactivation, whereas scorpion β 
toxins bind to site 4 of the channel and shift the threshold for channel activation to more 
negative potentials. 
 
Three classes of NaV channel toxins (Types I–III) have been isolated from sea anemones. 
They all have a similar pharmacological profile to scorpion α toxins and Family 4 NaSpTxs 
in that they delay channel inactivation by binding to site 3 (Bosmans and Tytgat, 2007). 
However, they have a distinct structural scaffold compared to both NaScTxs and NaSpTxs 
(Norton, 1991). Type 1 and Type II toxins typically comprise 46–49 residues with six 
cysteine residues arranged into three disulfide bridges, whereas Type III toxins are much 
shorter, typically comprising 27–32 residues, but also with three disulfide bonds (Norton, 
1991; Honma and Shiomi, 2006; Bosmans and Tytgat, 2007; Moran et al., 2009). In none of 
the three classes of sea anemone NaV toxins do the three disulfide bonds form an ICK motif, 
and none of the 3D scaffolds resemble those of NaScTxs or NaSpTxs. 
 
Three major classes of NaV channel toxins have been isolated from the venoms of marine 
cone snails: the µ-, δ-, and µO-conotoxins. The µ-conotoxins isolated from fish-hunting cone 
snails are small peptides (~20 residues) with three disulfide bonds that are often selective for 
the skeletal muscle NaV1.4 subtype (Ekberg et al., 2008; Wilson et al., 2011). They do not 
structurally resemble NaV channel toxins from spiders, scorpions or sea anemones. Moreover, 
in striking contrast with these latter toxins, the µ-conotoxins are pore blockers rather than 
gating modifiers that compete with TTX and saxitoxin for binding to neurotoxin receptor site 
1 (see Fig. 2) (Ekberg et al., 2008). 
 
Despite their vastly different primary structures and dissimilar modes of action, the δ- and 
µO-conotoxins are evolutionary related members of the O-superfamily with similar 3D 
scaffolds (Heinemann and Leipold, 2007). They comprise 29–31 residues with three 
conserved disulfide bonds that form an ICK motif. Hence, they are structural related to those 
families of NaSpTxs that also contain an ICK motif. The δ-conotoxins delay channel 
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inactivation, resulting in prolongation of action potentials, and hence they functionally 
resemble scorpion α toxins and Family 4 NaSpTxs. However, unlike these arachnid toxins 
that bind to channel site 3, the δ-conotoxins are the defining pharmacology for neurotoxin 
receptor site 6 on vertebrate NaV channels (see Fig. 2). In contrast to the δ-conotoxins, 
µO-conotoxins compete with β scorpion toxins for binding to neurotoxin receptor site 4 and 
they appear to block sodium flow by hindering activation of the voltage sensor in channel 
domain II, thereby preventing channel opening (Leipold et al., 2007). 
 
In summary, while several classes of NaSpTxs functionally resemble NaV channel toxins 
from other venomous animals, their only structural relatives are the δ- and µO-contoxins from 
the venom of marine cone snails. It is remarkable that two such taxonomically diverse 
animals, one confined to marine environments and the other a terrestrial predator, have 
evolved such similar molecular scaffolds for targeting the NaV channels of their prey. 
 
NaSpTxs as insecticides and pharmacological tools 
The 12 classes of NaSpTxs described here present a range of different pharmacologies with 
respect to their binding site on NaV channels and their modulation of channel function. For 
example, some toxin classes delay channel inactivation (e.g., Family 4) while others alter the 
voltage-dependence of channel activation (e.g., Family 10). Consequently many NaSpTxs 
have become valuable tools for probing the pharmacology and biophysics of NaV channels 
(Bosmans and Swartz, 2010). 
 
Some NaSpTxs are also promising leads for bioinsecticide development due to their potency 
against insect pests and minimal activity, if any, in vertebrates (Maggio et al., 2010; Windley 
et al., 2012). Many of the peptides in Families 10–12, for example, display the type of 
phyletic selectivity that is desirable for an insecticide. In contrast, many of the peptides in 
Families 3–6 display a high degree of vertebrate lethality and therefore they would not be 
suitable as either pharmacological or insecticidal agents. Because venom-derived NaV channel 
modulators are genetically encoded, transgenes encoding the peptides can be incorporated 
into crop plants and entomopathogens in order to deliver them to targeted insect pests 
(Tedford et al., 2004; Windley et al., 2012). For example, the insecticidal potency of the 
Autographa californica nuclear polyhedrosis baculovirus was significantly improved by 
engineering it to express a transgene encoding µ-AGTX-Aa1d (µ-Aga IV) from NaSpTx 
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Family 10 (Prikhod'ko et al., 1996).  
NaSpTxs as therapeutic leads 
The extremely high stability, specificity, and potency of venom peptides, which in the case of 
spiders is the result of hundreds of millions of years of evolutionary fine tuning, have made 
them a valuable source of natural products for drug discovery (Lewis and Garcia, 2003; 
Escoubas and Bosmans, 2007; Fox and Serrano, 2007; Escoubas and King, 2009; Vetter et al., 
2011). There are now six FDA-approved drugs derived from venom peptides or proteins, with 
a further ten in clinical trials and many more in various stages of preclinical development 
(King, 2011). Thus, the vast number of NaV channel modulators isolated from spider venoms 
begs the questions of whether any of these peptides might be useful therapeutically. 
 
NaV channels are the target of several classes of therapeutics such as local anaesthetics (e.g. 
lidocaine and ropivacaine) and antiarrhythmics (e.g., mexiletine and flecainide), as well as 
anticonvulsants used to treat epilepsy or bipolar disorder (e.g., lamotrigine, carbamazepine, 
and phenytoin) (Clare et al., 2000; England and de Groot, 2009). Moreover, while most 
tricyclic antidepressants (e.g., amitriptyline and imipramine) are serotonin–norepinephrine 
reuptake inhibitors, they also inhibit NaV channels (Nicholson et al., 2002; Dick et al., 2007). 
However, currently, the major pharmaceutical interest in NaV channels stems from their 
involvement in pain. Indeed, many of the NaV channel drugs described above are now used 
for treating various types of pain, particularly post-operative and neuropathic pain. 
 
Normal pain is a key adaptive response that serves to limit our exposure to potentially 
damaging or life-threatening events. In contrast, aberrant long-lasting pain transforms this 
adaptive response into a debilitating and often poorly managed disease. About 20% of adults 
suffer from chronic pain, with the incidence increasing to 50% for those older than 65 
(Brennan et al., 2007). There are few drugs available for treating chronic pain and most have 
limited efficacy, dose-limiting side-effects, and in some cases the potential for addiction 
(Carinci and Mao, 2010). Hence, there is much interest in developing novel pain medications 
that have minimal or no side-effects and that do not have problems of tolerance and addiction. 
 
Each of the nine NaV channel subtypes has a different anatomical distribution that determines 
their biological function. For example, NaV1.5 is restricted to the heart where it is critical for 
the rising phase of the cardiac action potential whereas NaV1.4 is restricted to muscle tissue 
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and is critical for muscle contraction (England and de Groot, 2009; England and Rawson, 
2010). The other seven subtypes are found in the central or peripheral nervous system. NaV1.7, 
NaV1.8 and NaV1.9 are selectively expressed in peripheral sensory neurons where they appear 
to play a key role in relaying pain signals to the spinal cord (Dib-Hajj et al., 2010). Of these 
subtypes, NaV1.7 has emerged as an exciting analgesic target based on several remarkable 
genetic studies. Gain-of-function mutations in the SNC9A gene encoding the pore-forming α 
subunit of NaV1.7 have been shown to cause painful inherited neuropathies (primary 
erythromelalgia and paroxysmal extreme pain disorder) (Yang et al., 2004; Fertleman et al., 
2006; Estacion et al., 2008). In contrast, loss-of-function mutations in SCN9A result in a 
congenital indifference to all forms of pain (Cox et al., 2006; Nilsen et al., 2009). Remarkably, 
apart from their complete inability to sense pain, loss of smell (anosmia) is the only other 
sensory impairment in individuals with this channelopathy (Nilsen et al., 2009; Weiss et al., 
2011; Rupasinghe et al., 2012).  
 
It is probable that the known analgesic effects of a number of nonspecific NaV channel 
blockers such as local anaesthetics, anticonvulsants, and tricyclic antidepressants are at least 
in part mediated through their effects on NaV1.7 (Nicholson et al., 2002; Dick et al., 2007; 
Levinson et al., 2012). However, the non-specific block of NaV channels by these drugs 
results in a very narrow therapeutic window, with CNS-related side-effects such as dizziness, 
headaches, and ataxia, as well as potential cardiac side-effects (Cummins and Rush, 2007; 
Krafte and Bannon, 2008). Thus, there is much interest in the development of subtype-
selective blockers of NaV1.7 (England and Rawson, 2010; Zuliani et al., 2010). In this regard, 
there are several reasons why NaSpTxs might be useful therapeutic leads for the development 
of NaV1.7-selective analgesics (Clare, 2010; England and Rawson, 2010; Saez et al., 2010). 
First, most NaSpTxs contain an ICK motif that provides them with tremendous chemical, 
thermal, and biological stability. Spider-venom ICK peptides are typically stable in human 
serum for several days and have half-lives in gastric fluid of >12 h (Saez et al., 2010). 
Notably, an ICK scaffold forms the core of the analgesic drug Prialt™ (Miljanich, 2004). 
Second, because NaSpTxs are gating modifiers rather then pore blockers they are more likely 
to be subtype selective than small compounds that bind in the highly conserved pore of the 
channel. Nevertheless, our understanding of the molecular basis of the potency and selectivity 
of NaSpTxs, which is critical for their progression to the clinic, is still rudimentary. Indeed, it 
is remarkable that we only know the complete NaV selectivity profile for a handful of peptides 
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in the 12 families of NaSpTxs. 	  
 
Table 1 summarises some of the salient features of each NaSpTx family, including an 
indication of their subtype preferences. Notably, peptides that potently block NaV1.5 tend to 
be lethal in rodents, consistent with the critical role of this subtype in cardiac function. This 
highlights the need to pinpoint the residues on these peptides that mediate their selectivity and 
potency in order to be able to rationally engineer improved versions that preferentially bind 
NaV1.7. This will be the major challenge in progressing these peptides to the clinic. On a 
positive note, however, peptides have already been isolated from Families 1–3 that potently 
block NaV1.7 (IC50 ≤ 51 nM) and that have at least some selectivity over other NaV subtypes. 
Moreover, it is worth noting that parenterally administered NaSpTxs are unlikely to cross the 
blood-brain barrier and enter the CNS, and therefore off-target activity at centrally located 
NaV subtypes is unlikely to be a therapeutic problem. 
 
In conclusion, it is clear that spiders have evolved a larger repertoire of NaV channel toxins 
than any other venomous animal. These NaSpTxs modulate NaV channels in a variety of 
different ways ranging from effects on the voltage-dependence of activation to the kinetics of 
channel inactivation. Many of these peptides have become useful pharmacological tools for 
studying the pharmacology and biophysics of NaV channels, while others are being developed 
as bioinsecticides due to their selective action on invertebrate NaV channels. In addition, 
many NaSpTxs are vertebrate-active and those with high potency and selectivity for certain 
NaV subtypes that are localised in peripheral pain pathways are being used as leads to develop 
novel classes of analgesics. Finally, it is worth noting that the 12 classes of NaSpTxs 
described here have been derived from only eight of the 110 extant families of spiders 
(Platnick, 1997). Thus, it is likely that additional classes of NaSpTxs will be discovered 
through better taxonomic sampling of the incredible diversity of spider venoms available. 
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Fig. 1: Ion channel modulators from spider venoms. Molecular targets of the 186 ion 
channel toxins listed in ArachnoServer (www.arachnoserver.org; accessed February 12, 
2012) (Herzig et al., 2011). The majority of toxins target voltage-gated ion channels (CaV, 
NaV, and KV), followed by calcium-activated potassium  (KCa) channels, mechanosensitive 
ion channels (MSC), transient receptor potential (TRP) channels, and acid-sensing ion 
channels (ASICs). Note that some toxins target more than one type of channel, and therefore 
the cumulative number of toxins in the histogram is >186. 
 
Fig. 2: Molecular architecture and pharmacology of NaV channels. The pore-forming α 
subunit of NaV channels is comprised of four homologous domains denoted I–IV connected 
by intracellular linkers. Each of these domains contains six transmembrane (TM) helical 
segments (labelled 1–6) joined by intra- or extracellular loops. TM segments 5 and 6 from 
each domain, along with the intervening membrane re-entrant loops (highlighted with a green 
box), come together to form the channel pore and the ion-selectivity filter at the extracellular 
end of the pore. TM segments 1–4 of each domain form the voltage-sensing units, as 
indicated for domain I; the highly positively charged TM segment 4 is primarily responsible 
for sensing changes in membrane polarization. Sodium channel inactivation is mediated by a 
short stretch of hydrophobic residues (the “inactivation gate”) in the intracellular linker 
connecting domains III and IV. Coloured regions represent neurotoxin receptor sites. The 
grey circles represent the outer (EEDD) and inner (DEKA) rings of amino acid residues that 
form the ion selectivity filter and constitute the proposed neurotoxin receptor site 1 for the 
water‐soluble guanidinium toxins TTX and saxitoxin. Some µ‐conotoxin binding sites overlap 
with those of TTX and are omitted for clarity. Nevertheless, we refer to sites 1a and 1b to 
distinguish between the different molecular determinants for µ-conotoxin and TTX/saxitoxin 
binding. In the case of receptor sites 3 and 4, only epitopes where mutagenesis of key residues 
leads to more than a five‐fold decrease in toxin binding affinity are highlighted. Note that TM 
segment 6 in domain I includes binding epitopes for both site 2 and site 5 toxins. The known 
binding sites for 8 of the 12 families of spider-venom NaV toxins (NaSpTxs) are indicated. “F” 
denotes toxin family (e.g., F2 indicates NaSpTx Family 2). While the δ-amaurobitoxins in 
Family 10 have been shown to bind to neurotoxin receptor site 4, peptides in this family have 
variable pharmacology and some may bind at other sites. Adapted from (Catterall et al., 2007; 
King et al., 2008a). 
33 
Fig. 3: NaSpTx families 1–4, 7 and 10. The consensus sequence is shown above each 
alignment, with the disulfide-bond connectivity indicated in blue. Asterisks denote C-terminal 
amidation. Toxin names are based on the rational nomenclature devised for spider-venom 
peptides (King et al., 2008b), as used in ArachnoServer and UniProt (King et al., 2008b). The 
structure of a representative member from each NaSpTx family is shown adjacent to each 
alignment: Family 1, µ-TRTX-Hh2a (PDB ID: 1MB6); Family 2, κ-TRTX-Gr1a (PDB ID: 
1D1H); Family 3, κ-TRTX-Gr2a (PDB ID: 1LUP); Family 4, δ-HXTX-Hv1a (PDB 
ID:1VTX); Family 7, κ-TRTX-Gr3a (PDB ID: 1S6X); Family 10, δ-AMATX-Pl1b (PDB ID: 
1V91). β-Strands are depicted in cyan, helices are red, and disulfide bridges are yellow. All 
spider photos were taken by Bastian Rast. 
 
Fig. 4: NaSpTx families 5, 6, 8, 9, 11 and 12. The consensus sequence is shown above each 
alignment, with the disulfide-bond connectivity indicated in blue. Dotted lines represent 
predicted disulfide-bond connectivities that have not been experimentally validated. Asterisks 
denote C-terminal amidation. Toxin names are based on the rational nomenclature devised for 
spider-venom peptides (King et al., 2008b), as used in ArachnoServer and UniProt. The 
structure of a representative member of Family 5 is shown adjacent to each alignment 
(β-HXTX-Mg1a; PDB ID: 2GX1). Disulfide bridges are coloured yellow. No structures are 
available for any member of the other NaSpTx families depicted in this figure. Spider photos 
are by Bastian Rast (M. gigas and P. reidyi) and Aloys Staudt (H. melloteei). 
 
 
